·	NON 1 0 1999
T.O. 1449	U.S. Department of Commercia

1_ of _1_

	Sheet _	
ATTY. DOCKET NO.	SERIAL NO.	
515-4167	09/355,210	
APPLICANT(S)		
Raffaello Giorgi et al.		
July 23, 1999	••	
FILING DATE	GROUP 1/2	

LIST OF PRIOR ART CITED BY APPLICANT

1653

U.S. PATENT DOCUMENTS										
DOCUMENT MUNISER	DATE	NAME '	CLASS	SUB	PILIM					
					Ш					
			.1.							
0										
		_			П					
					П					
					П					
			1		П					
					Ш					
		·	·							

^							_ 10	KE I I	PATENT 9000	RM15			
12				000	LNENT	MUNE	ER		DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
9	BA	9	3	2	1	2	2	7	10/28/93	PCT			
					-								
										1			
										1	1 -		
										-			
		_			L			<u> </u>	<u> </u>	<u> </u>	1	<u> </u>	

(OTHER PRIOR ART (INCLUDING AUTHOR, TITLE, DATE, PERTIMENT PAGES, EYC.)

European Journal of Pharmacology, 241(1993) 17-25: "Tachykinin-Mediated Respiratory Effects in Conscious Guines Pigs:
-Modulation by NK-1 and NK-2 Receptor Antagonists". Elizabeth M. Kudlacz et al.

P Psychopharmacology (1995) 121:186-191: "The Anxiolytic-like Activity of GR159897, a Mon-Peptide NK-2 Recentor Antagonist, in Rodent and Primate Models of Anxiety": D. M. Walsh et al.

Br. J. Pharmacol. (1991). 104. 355-360; "Pharmacological <u>Specificity of Novel, Synthetic. Cyclic Peotides as</u> Antagonists at Tachykinin Receptors"; A.T. McKnight et al.

Acournal of Medicinal Chemistry, 1994, Vol. 37, No. 21; "Influence of Lipophilicity on the Biological Activity of Cyclic Pseudopoptide NK-2 Receptor Antasonists"; Laura Quartara et al.

EXAMINE

DATE CONSIDERED

EXMINER: Initial if reference is considered, whether or not citation is in conformance with NEFP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to rmance with MPEP 609; Draw Line application